Current:Home > InvestTesla again seeks shareholder approval for Musk's 2018 pay voided by judge -QuantumProfit Labs
Tesla again seeks shareholder approval for Musk's 2018 pay voided by judge
View
Date:2025-04-22 19:23:59
Tesla TSLA.O on Wednesday asked shareholders to reaffirm their approval of CEO Elon Musk's record-breaking $56 billion compensation that was set in 2018, but was rejected by a Delaware judge in January.
The re-vote comes ahead of next week's quarterly earnings for Tesla, which is grappling with weak demand as well as a reputational hit to Musk from his political leanings and approval of an antisemitic conspiracy theory last year.
"Elon has not been paid for any of his work for Tesla for the past six years...," Board Chairperson Robyn Denholm wrote in a letter included in the regulatory filing. "That strikes us – and the many stockholders from whom we already have heard – as fundamentally unfair."
Tesla's board, which includes Musk's brother Kimbal Musk, has repeatedly come under fire for its close ties with the billionaire.
In seeking a re-vote, Tesla is using a section of Delaware law that allows companies to ratify actions that are technically defective such as selling stock before the board approves an increase in shares, but not always controversial.
The board's special committee, which was formed to insulate the process of setting the pay from allegations of Musk's influence, said it cannot predict if its "novel" approach of getting a re-approval would be proper under Delaware law.
The largest pay package in corporate America has no salary or cash bonus and sets rewards based on Tesla's market value rising to as much as $650 billion over the next 10 years from 2018.
Tesla in 2018 said the grant could be worth $56 billion, though the amount depends on Tesla's stock price. The package currently is worth about $40 billion.
Tesla shares fell nearly 2% after the company's latest move, putting its market value on track to close below $500 billion for the first time in about a year.
After re-vote, Musk may appeal
Musk's pay was rejected by Judge Kathaleen McCormick of Delaware's Court of Chancery, who termed the compensation as "an unfathomable sum" that was unfair to shareholders.
If Tesla shareholders vote in favor, it would not automatically entitle Musk to the money, Eric Talley, a Columbia Law School professor, said.
Approval would fix the flawed 2018 shareholder vote process, Talley said, but Musk would need to appeal to overturn the findings that he controlled the negotiation process that led to the record-breaking compensation.
Musk is expected to appeal the ruling later this year after the trial court determines how much the shareholder's legal team should be paid by Tesla.
The original pay package negotiations were found by judge McCormick to have been heavily influenced by Musk, who after the ruling tweeted - "Never incorporate your company in the state of Delaware".
Brian Dunn, a visiting lecturer in Cornell University’s School of Industrial and Labor Relations who consults boards on compensation, said the new vote was evidence the board was compromised.
“No one has ever said he shouldn’t get paid, but let’s remember the initial plan was flawed beyond its unprecedented magnitude,” Dunn said.
On Wednesday, Tesla also urged investors to approve its plan to move the company's state of incorporation from Delaware to Texas, potentially escalating a tussle between Musk and the state of Delaware.
Earlier this year, Musk shifted the location of incorporation of his rocket company SpaceX to Texas and brain-chip startup Neuralink to Nevada from Delaware.
Job news:Tesla to lay off 10% of its global workforce, reports say: 'It must be done'
Tesla has also proposed board re-appointments for Kimbal Musk and James Murdoch, son of media tycoon Rupert Murdoch.
Tesla's mounting concerns
Tesla's shares have lost more than 36% of their value so far this year as electric-vehicle sales slowed down globally.
Developments such as scrapping plans for an affordable EV and deciding to cut at least 10% of its staff have also left analysts questioning the company's strategy.
veryGood! (9591)
Related
- John Galliano out at Maison Margiela, capping year of fashion designer musical chairs
- COVID Risk May Be Falling, But It's Still Claiming Hundreds Of Lives A Day
- 4 ways the world messed up its pandemic response — and 3 fixes to do better next time
- House Judiciary chair Jim Jordan seeks unredacted DOJ memo on special counsel's Trump probes
- Alex Murdaugh’s murder appeal cites biased clerk and prejudicial evidence
- Troubled by Trump’s Climate Denial, Scientists Aim to Set the Record Straight
- Why Prince Harry Didn't Wear His Military Uniform to King Charles III's Coronation
- Bernie Sanders’ Climate Plan: Huge Emissions Cuts, Emphasis on Environmental Justice
- B.A. Parker is learning the banjo
- Legal fights and loopholes could blunt Medicare's new power to control drug prices
Ranking
- FACT FOCUS: Inspector general’s Jan. 6 report misrepresented as proof of FBI setup
- Maps, satellite images show Canadian wildfire smoke enveloping parts of U.S. with unhealthy air
- Bernie Sanders’ Climate Plan: Huge Emissions Cuts, Emphasis on Environmental Justice
- Today’s Climate: June 11, 2010
- Will the 'Yellowstone' finale be the last episode? What we know about Season 6, spinoffs
- Calif. Lawmakers Rush to Address Methane Leak’s Dangers
- Daily 'breath training' can work as well as medicine to reduce high blood pressure
- The heartbreak and cost of losing a baby in America
Recommendation
Former longtime South Carolina congressman John Spratt dies at 82
Overlooked Tiny Air Pollutants Can Have Major Climate Impact
All the Ways Queen Elizabeth II Was Honored During King Charles III's Coronation
City in a Swamp: Houston’s Flood Problems Are Only Getting Worse
Bill Belichick's salary at North Carolina: School releases football coach's contract details
A box of 200 mosquitoes did the vaccinating in this malaria trial. That's not a joke!
Senate Finance chair raises prospect of subpoena for Harlan Crow over Clarence Thomas ties
Merck sues U.S. government over plan to negotiate Medicare drug prices, claiming extortion